Summary of Use during Lactation

No information is available on the clinical use of daratumumab during breastfeeding. Because daratumumab is a large protein molecule with a molecular weight of 148,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] However, daratumumab is administered with lenalidomide, pomalidomide, or thalidomide, three drugs that have no information on use in nursing mothers. For this reason, the manufacturer recommends that women receiving daratumumab should not breastfeed.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]

Substance Name

Daratumumab

CAS Registry Number

945721-28-8

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal, Humanized

Antineoplastic Agents